Elisabeth Bendstrup

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Progressive fibrosing interstitial lung diseases : current practice in diagnosis and management. / Wijsenbeek, Marlies; Kreuter, Michael; Olson, Amy; Fischer, Aryeh; Bendstrup, Elisabeth; Wells, Christopher D.; Denton, Christopher P.; Mounir, Baher; Zouad-Lejour, Leila; Quaresma, Manuel; Cottin, Vincent.

In: Current Medical Research and Opinion, Vol. 35, No. 11, 2019, p. 2015-2024.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Wijsenbeek, M, Kreuter, M, Olson, A, Fischer, A, Bendstrup, E, Wells, CD, Denton, CP, Mounir, B, Zouad-Lejour, L, Quaresma, M & Cottin, V 2019, 'Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management', Current Medical Research and Opinion, vol. 35, no. 11, pp. 2015-2024. https://doi.org/10.1080/03007995.2019.1647040

APA

Wijsenbeek, M., Kreuter, M., Olson, A., Fischer, A., Bendstrup, E., Wells, C. D., Denton, C. P., Mounir, B., Zouad-Lejour, L., Quaresma, M., & Cottin, V. (2019). Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Current Medical Research and Opinion, 35(11), 2015-2024. https://doi.org/10.1080/03007995.2019.1647040

CBE

Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V. 2019. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Current Medical Research and Opinion. 35(11):2015-2024. https://doi.org/10.1080/03007995.2019.1647040

MLA

Vancouver

Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Current Medical Research and Opinion. 2019;35(11):2015-2024. https://doi.org/10.1080/03007995.2019.1647040

Author

Wijsenbeek, Marlies ; Kreuter, Michael ; Olson, Amy ; Fischer, Aryeh ; Bendstrup, Elisabeth ; Wells, Christopher D. ; Denton, Christopher P. ; Mounir, Baher ; Zouad-Lejour, Leila ; Quaresma, Manuel ; Cottin, Vincent. / Progressive fibrosing interstitial lung diseases : current practice in diagnosis and management. In: Current Medical Research and Opinion. 2019 ; Vol. 35, No. 11. pp. 2015-2024.

Bibtex

@article{3fba2f7472bd45fa8f43c36d144cfd91,
title = "Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management",
abstract = "Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis and management of non-IPF ILDs using data from a survey of physicians and from US insurance claims. Methods: Pulmonologists, rheumatologists and internists in France, Germany, Italy, Japan, Spain, UK and US who had managed ≥10 patients with non-IPF ILDs in the past year, including those with progressive fibrosing ILDs, completed an online survey. Data on US insurance and prescription claims were obtained from a repository that aggregates data on claims routed from providers or pharmacies to payers. Results: In May–June 2017, 243 pulmonologists, 203 rheumatologists and 40 internists completed an online survey. Respondents estimated that 18–32% of patients diagnosed with non-IPF ILDs develop progressive fibrosis and that time from symptom onset to death in these patients was 61–80 months. Drug treatment was given to 50–75% of patients with non-IPF progressive fibrosing ILDs. Reasons for patients not being treated included that physicians considered patients to have mild or slowly progressing disease, or did not believe that available treatments are effective or well tolerated. Corticosteroids were the preferred first-line treatment for all types of non-IPF ILD. There was considerable heterogeneity in preferences for second- and third-line treatments. US insurance claims data from 3823 patients indicated that, in 2016, 50–75% of patients with ILDs received drug treatment (mostly corticosteroids) for their ILD. Conclusions: Physicians estimate that 18–32% of patients diagnosed with non-IPF ILDs develop a progressive fibrosing phenotype and that these patients experience significant delays in the diagnosis of ILD and the detection of progressive fibrosis. Between 25% and 50% of patients with progressive fibrosing ILDs do not receive drug therapy. There is an unmet need for effective and well tolerated treatments for progressive fibrosing ILDs.",
keywords = "Disease management, drug therapy, immunosuppression, pulmonologist, rheumatologist, survey",
author = "Marlies Wijsenbeek and Michael Kreuter and Amy Olson and Aryeh Fischer and Elisabeth Bendstrup and Wells, {Christopher D.} and Denton, {Christopher P.} and Baher Mounir and Leila Zouad-Lejour and Manuel Quaresma and Vincent Cottin",
year = "2019",
doi = "10.1080/03007995.2019.1647040",
language = "English",
volume = "35",
pages = "2015--2024",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Taylor & Francis ",
number = "11",

}

RIS

TY - JOUR

T1 - Progressive fibrosing interstitial lung diseases

T2 - current practice in diagnosis and management

AU - Wijsenbeek, Marlies

AU - Kreuter, Michael

AU - Olson, Amy

AU - Fischer, Aryeh

AU - Bendstrup, Elisabeth

AU - Wells, Christopher D.

AU - Denton, Christopher P.

AU - Mounir, Baher

AU - Zouad-Lejour, Leila

AU - Quaresma, Manuel

AU - Cottin, Vincent

PY - 2019

Y1 - 2019

N2 - Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis and management of non-IPF ILDs using data from a survey of physicians and from US insurance claims. Methods: Pulmonologists, rheumatologists and internists in France, Germany, Italy, Japan, Spain, UK and US who had managed ≥10 patients with non-IPF ILDs in the past year, including those with progressive fibrosing ILDs, completed an online survey. Data on US insurance and prescription claims were obtained from a repository that aggregates data on claims routed from providers or pharmacies to payers. Results: In May–June 2017, 243 pulmonologists, 203 rheumatologists and 40 internists completed an online survey. Respondents estimated that 18–32% of patients diagnosed with non-IPF ILDs develop progressive fibrosis and that time from symptom onset to death in these patients was 61–80 months. Drug treatment was given to 50–75% of patients with non-IPF progressive fibrosing ILDs. Reasons for patients not being treated included that physicians considered patients to have mild or slowly progressing disease, or did not believe that available treatments are effective or well tolerated. Corticosteroids were the preferred first-line treatment for all types of non-IPF ILD. There was considerable heterogeneity in preferences for second- and third-line treatments. US insurance claims data from 3823 patients indicated that, in 2016, 50–75% of patients with ILDs received drug treatment (mostly corticosteroids) for their ILD. Conclusions: Physicians estimate that 18–32% of patients diagnosed with non-IPF ILDs develop a progressive fibrosing phenotype and that these patients experience significant delays in the diagnosis of ILD and the detection of progressive fibrosis. Between 25% and 50% of patients with progressive fibrosing ILDs do not receive drug therapy. There is an unmet need for effective and well tolerated treatments for progressive fibrosing ILDs.

AB - Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis and management of non-IPF ILDs using data from a survey of physicians and from US insurance claims. Methods: Pulmonologists, rheumatologists and internists in France, Germany, Italy, Japan, Spain, UK and US who had managed ≥10 patients with non-IPF ILDs in the past year, including those with progressive fibrosing ILDs, completed an online survey. Data on US insurance and prescription claims were obtained from a repository that aggregates data on claims routed from providers or pharmacies to payers. Results: In May–June 2017, 243 pulmonologists, 203 rheumatologists and 40 internists completed an online survey. Respondents estimated that 18–32% of patients diagnosed with non-IPF ILDs develop progressive fibrosis and that time from symptom onset to death in these patients was 61–80 months. Drug treatment was given to 50–75% of patients with non-IPF progressive fibrosing ILDs. Reasons for patients not being treated included that physicians considered patients to have mild or slowly progressing disease, or did not believe that available treatments are effective or well tolerated. Corticosteroids were the preferred first-line treatment for all types of non-IPF ILD. There was considerable heterogeneity in preferences for second- and third-line treatments. US insurance claims data from 3823 patients indicated that, in 2016, 50–75% of patients with ILDs received drug treatment (mostly corticosteroids) for their ILD. Conclusions: Physicians estimate that 18–32% of patients diagnosed with non-IPF ILDs develop a progressive fibrosing phenotype and that these patients experience significant delays in the diagnosis of ILD and the detection of progressive fibrosis. Between 25% and 50% of patients with progressive fibrosing ILDs do not receive drug therapy. There is an unmet need for effective and well tolerated treatments for progressive fibrosing ILDs.

KW - Disease management

KW - drug therapy

KW - immunosuppression

KW - pulmonologist

KW - rheumatologist

KW - survey

UR - http://www.scopus.com/inward/record.url?scp=85070197029&partnerID=8YFLogxK

U2 - 10.1080/03007995.2019.1647040

DO - 10.1080/03007995.2019.1647040

M3 - Journal article

C2 - 31328965

AN - SCOPUS:85070197029

VL - 35

SP - 2015

EP - 2024

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 11

ER -